A PHASE I/II STUDY OF A NOVEL INDIBULIN DOSING SCHEDULE FOR THE TREATMENT OF METASTATIC BREAST CANCER.

Trial Profile

A PHASE I/II STUDY OF A NOVEL INDIBULIN DOSING SCHEDULE FOR THE TREATMENT OF METASTATIC BREAST CANCER.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs Indibulin (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ZIOPHARM Oncology
  • Most Recent Events

    • 29 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 30 Jan 2012 Planned end date changed from 1 Nov 2011 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 03 May 2010 New source identified and integrated (ClinicalTrials.gov record no. NCT01113970).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top